Hospital Infantil de Niño Jesús de Barranquilla (HINJ) Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2021
NCT04597437
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hospital Infantil de Niño Jesús de Barranquilla (HINJ)

Active Ingredients

Drugs in Phase 1 Trials (1)

zanamivir (relenza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dengue (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1